Literature DB >> 7707534

Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription.

D A Fallows1, S P Goff.   

Abstract

Hepadnaviruses replicate by reverse transcription of an RNA intermediate within subviral core particles in the cytoplasm of infected hepatocytes. Recognition of the epsilon encapsidation signal located on the 5' end of the pregenomic RNA by the viral polymerase occurs early in core particle assembly. The epsilon sequences contain a set of nested inverted repeats which form a stable stem-loop structure shown to play a role in RNA packaging and recently implicated as the site of initiation of minus-strand DNA synthesis. We have introduced a variety of site-directed mutations into the epsilon sequences of human hepatitis B virus to study their effects on viral replication in transfected HuH7 cells. We have identified two classes of mutations: those which adversely affect packaging and those which package RNA but adversely affect DNA synthesis. Analysis of these mutants has allowed us to identify separate features of the epsilon cis-acting signal which function in the processes of RNA packaging and reverse transcription.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707534      PMCID: PMC189007     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands.

Authors:  D L Garbers
Journal:  Cell       Date:  1992-10-02       Impact factor: 41.582

2.  Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis.

Authors:  J M Lien; C E Aldrich; W S Mason
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

4.  Initiation and termination of duck hepatitis B virus DNA synthesis during virus maturation.

Authors:  J M Lien; D J Petcu; C E Aldrich; W S Mason
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA.

Authors:  J K Christman; M Gerber; P M Price; C Flordellis; J Edelman; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Replication strategy of human hepatitis B virus.

Authors:  H Will; W Reiser; T Weimer; E Pfaff; M Büscher; R Sprengel; R Cattaneo; H Schaller
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

8.  Biochemical and genetic evidence for the hepatitis B virus replication strategy.

Authors:  C Seeger; D Ganem; H E Varmus
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

9.  Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis.

Authors:  J R Pollack; D Ganem
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line.

Authors:  C M Chang; K S Jeng; C P Hu; S J Lo; T S Su; L P Ting; C K Chou; S H Han; E Pfaff; J Salfeld
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  50 in total

1.  In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90.

Authors:  J Hu; D Anselmo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase.

Authors:  Feng Cao; Matthew P Badtke; Lisa M Metzger; Ermei Yao; Babatunde Adeyemo; Yunhao Gong; John E Tavis
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Hepatitis B virus replication.

Authors:  Juergen Beck; Michael Nassal
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.

Authors:  Daniel J Tenney; Ronald E Rose; Carl J Baldick; Steven M Levine; Kevin A Pokornowski; Ann W Walsh; Jie Fang; Cheng-Fang Yu; Sharon Zhang; Charles E Mazzucco; Betsy Eggers; Mayla Hsu; Mary Jane Plym; Patricia Poundstone; Joanna Yang; Richard J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

5.  Evidence that the 5'-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA.

Authors:  J K Jeong; G S Yoon; W S Ryu
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Distinct requirements for primary sequence in the 5'- and 3'-part of a bulge in the hepatitis B virus RNA encapsidation signal revealed by a combined in vivo selection/in vitro amplification system.

Authors:  A Rieger; M Nassal
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

7.  A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion.

Authors:  Anne Marie Dougherty; Haitao Guo; Gael Westby; Yuanjie Liu; Ender Simsek; Ju-Tao Guo; Anand Mehta; Pamela Norton; Baohua Gu; Timothy Block; Andrea Cuconati
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

8.  Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Authors:  S Levine; D Hernandez; G Yamanaka; S Zhang; R Rose; S Weinheimer; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Protein-primed terminal transferase activity of hepatitis B virus polymerase.

Authors:  Scott A Jones; Jianming Hu
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.